Physician profile
Thomas D Ilic
NPI 1912438417
$324,272.45
in general payments reported to CMS, 2019-2025
7 companies · $209K in 2025
The $209K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $141 · 2023: $143 · 2024: $115K · 2025: $209K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $153K · Honoraria: $105K · Travel and Lodging: $49K · Food and Beverage: $8,830 · Consulting Fee: $8,115 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $153,320.00 |
| Honoraria | $105,050.00 |
| Travel and Lodging | $48,704.89 |
| Food and Beverage | $8,830.34 |
| Consulting Fee | $8,115.00 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $188,857.35 | 2022-2025 | Spravato, Invega Sustenna |
| Axsome Therapeutics, INC. | $124,210.46 | 2024-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $8,337.31 | 2025 | Cobenfy |
| Abbvie INC. | $2,314.88 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $254.71 | 2025 | Uzedy |
| Janssen Scientific Affairs, LLC | $179.82 | 2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $117.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Ilic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.